Passage Bio ( (PASG) ) just unveiled an update.
Passage Bio, a clinical stage genetic medicines company, presented promising preclinical and interim clinical data for its PBFT02 gene therapy at the ESGCT Annual Congress. PBFT02 uses an AAV1 vector to deliver GRN genes to increase progranulin levels, potentially altering the course of neurodegenerative diseases like frontotemporal dementia. The data showed significant progranulin elevation in the central nervous system, with a well-tolerated safety profile, positioning PBFT02 as a potential breakthrough in treating such conditions.
Learn more about PASG stock on TipRanks’ Stock Analysis page.
